BioSpace News Archive

Centinel Spine®, LLC announced that in an effort to increase the availability of two-level lumbar total disc replacement to individuals experiencing degeneration of the intervertebral discs, the American Medical Association has accepted the addition of a new add-on Category I Current Procedural Terminology code for a second level of lumbar TDR.

Today, Health Canada received a submission from Moderna seeking authorization for the use of its Spikevax COVID-19 vaccine in children 6 to 11 years of age

Vector Laboratories, the market leader in the development and manufacture of labeling and detection reagents for biomedical research, today announced that it has promoted Pamela James, Ph.D., to the position of Vice President, Product, effective immediately.

Acorn Technologies, a groundbreaking innovator in the semiconductor and telecommunications markets since 1998, today announced a research collaboration with Jean-Pierre Raskin, PhD, a full professor at the Université catholique de Louvain (UCLouvain), Belgium’s largest French-speaking university.

Gene Therapy has enjoyed exponential growth over the past decade due to the evolution of the technology, significant investment in the biotechnology sector, and the emergence of approved drugs that have broken through an important barrier.

Pfizer Inc. today announced it is seeking Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, PAXLOVID™ (PF-07321332; ritonavir), for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalizations or death.

CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, urged stockholders to register 24 hours prior to the meeting time in order to participate in this meeting.

Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the hiring of Mr. David Barthel as the Chief Executive Officer for Marizyme.

SCIEX, a global leader in life science analytical technologies, and RedShiftBio®, a provider of next-generation platform technology enabling measurements of previously undetectable structure changes in biomolecules, have entered into a supply relationship to help more biopharmaceutical labs access the critical data necessary to close the developability gap.

Rockwell Medical, Inc. announced the publication of results in the Journal of Bioequivalence & Bioavailability from a study designed to investigate the co-administration of intravenous Ferric Pyrophosphate Citrate with unfractionated heparin as an admixture via the HD-machine syringe pump.